Paragon Care

[jerez1]

Empresa australiana de suminstros de equipamientos médicos. Lleva años en crecimiento. Ahora la veo infravalorada y con buena proyección para los próximos años.
Los ratios financieros los veo positivos
Per actual 12, ROE 12%, Precio valor en libros 1,5,

http://www.4-traders.com/PARAGON-CAR...14/financials/





Análisis de compañía

http://www.paragoncare.com.au/wp-content/uploads/PGC-Paragon-Care-Equity-Report-Shaw-and-Partners_v2017-07-04.pdf

[luscofusco]

Le eché un ojo muy por encima, lo que no me ha gustado:

- Dilución de capital, 2014 58m acciones, actuales 161 (casi un 300%).
- Márgenes muy ajustados, comenzaron a mejorar el año pasado pero hay que ver si son sostenibles.
- Sin ventajas competitivas (o eso dice Morningstar).

[jerez1]

Le eché un ojo muy por encima, lo que no me ha gustado:

- Dilución de capital, 2014 58m acciones, actuales 161 (casi un 300%).
- Márgenes muy ajustados, comenzaron a mejorar el año pasado pero hay que ver si son sostenibles.
- Sin ventajas competitivas (o eso dice Morningstar).

Tampoco digo que sea un superchollo, pero le veo crecimiento en el sector y pais que está, acompañan noticias positivas. Y me gusta a este precio el per bajo y Roe no está mal. Deuda controlada. Hay empresas que aunque no tenga ventajas competitivas claras, pueden dar una buena revalorización en medio plazo.

un saludo

[jerez1]

Tampoco digo que sea un superchollo, pero le veo crecimiento en el sector y pais que está, acompañan noticias positivas. Y me gusta a este precio el per bajo y Roe no está mal. Deuda controlada. Hay empresas que aunque no tenga ventajas competitivas claras, pueden dar una buena revalorización en medio plazo.

un saludo

Recommendation
PGC’s recent acquisitions (predominantly consumables and service businesses) have been performing better than recognised (see page 5), which has significant implications for the growth it is likely to deliver in the future both from its current businesses and the acquisitions that are clearly going to be made. The long term growth we expect sets it apart from comparative companies with similar health related product offerings and makes us think more about the way in which GUD has recently been re-rated in response to its acquisition/divestment program. We believe, based on PGC’s register and limited broker coverage that mainstream investors are yet to consider this and that PGC is essentially undiscovered. Our 12 month TP is $0.95, however with acquisitions we will look to reassess our TP again. BUY.


http://www.paragoncare.com.au/wp-con...2017-07-04.pdf

[jerez1]

Le eché un ojo muy por encima, lo que no me ha gustado:

- Dilución de capital, 2014 58m acciones, actuales 161 (casi un 300%).
- Márgenes muy ajustados, comenzaron a mejorar el año pasado pero hay que ver si son sostenibles.
- Sin ventajas competitivas (o eso dice Morningstar).

Publicación de resultados. Sube un 11%!!!!

http://www.paragoncare.com.au/wp-content/uploads/PGC_Full-Year-Results-Investor-Presentation-2017-08-07.pdf

[jerez1]

Publicación de resultados. Sube un 11%!!!!

http://www.paragoncare.com.au/wp-con...2017-08-07.pdf

Otro 3% arriba.
El crecimiento ha sido muy bueno tanto en Ebitda, como en cash flow, además reducen considerablemente la deuda.

[jerez1]

Otro 3% arriba.
El crecimiento ha sido muy bueno tanto en Ebitda, como en cash flow, además reducen considerablemente la deuda.

Paragon surges, with more upside possible

Published on: Aug 9, 2017 | by Trevor Hoey
Shares in healthcare equipment group, Paragon Care (ASX: PGC) spiked from Friday’s close of 81 cents to hit an intraday high of 93 cents on Monday. This occurred under the highest daily volumes recorded in the last five years. The intraday high was repeated again on Tuesday.
It should be noted share trading patterns should not be used as the basis for an investment as they may or may not be replicated. Those considering this stock should seek independent financial advice.
Interestingly, the provider of medical equipment, devices and consumables to the health care industry has traded as high as 94 cents during its circa 10 year history as an ASX listed entity, and it could be technical selling that is currently keeping a lid on the company’s share price.
Certainly, the result appeared to warrant a rerating as the impressive key financials below indicate.

While revenues were broadly in line with management’s guidance, there was a slight outperformance at the EBITDA line.
Brokers see further upside

As indicated by John Hester from Bell Potter, PGC is best assessed on its earnings per share performance. As a growth by acquisition story, the company has issued new shares over the last two years, effectively diluting earnings per share.
Consequently, using this measure takes into account the impact of issuing scrip for all or part consideration in relation to acquisitions.
Bell Potter is forecasting earnings per share to increase to 6.9 cents in fiscal 2018, implying a PE multiple of 13.4 relative to its 12 month high of 93 cents. This represents a 50% discount to the broader sector average PE multiple of 26.8.
Of course broker projections and price targets are only estimates and may not be met.
However, some of the larger blue-chip companies tend to push the average multiple higher than what is normally representative of the mid-tier players.
The broker reactions have been interesting with Bell Potter maintaining its buy recommendation and slightly increasing its price target to $1.02.
By contrast, Ian Christie from Argonaut views the current price as good value with his valuation of $1.12 implying upside of 20% to the group’s current trading range. He expects PGC to achieve organic growth of 10% per annum over the next two years with EBITDA margins of circa 15%.
Again, broker projections should only be taken into account with all publically available information.

PGC’s Managing Director, Mark Simari was relatively upbeat with his outlook statement, saying that the company is well-placed to deliver growth in future years, driven by a combination of organic and acquisitive growth with the e-health sector offering a new revenue stream.
The addition of services and maintenance contracts will also help, as they provide recurring income to complement revenues generated from the sale of new equipment.

[jerez1]

Le eché un ojo muy por encima, lo que no me ha gustado:

- Dilución de capital, 2014 58m acciones, actuales 161 (casi un 300%).
- Márgenes muy ajustados, comenzaron a mejorar el año pasado pero hay que ver si son sostenibles.
- Sin ventajas competitivas (o eso dice Morningstar).

Paragon Care : Acquisition of Medtek Pty Ltd


http://www.4-traders.com/PARAGON-CAR...-Ltd-24940932/

[jerez1]

Empresa australiana de suminstros de equipamientos médicos. Lleva años en crecimiento. Ahora la veo infravalorada y con buena proyección para los próximos años.
Los ratios financieros los veo positivos
Per actual 12, ROE 12%, Precio valor en libros 1,5,

http://www.4-traders.com/PARAGON-CAR...14/financials/





Análisis de compañía

http://www.paragoncare.com.au/wp-content/uploads/PGC-Paragon-Care-Equity-Report-Shaw-and-Partners_v2017-07-04.pdf

Corregida, debe dar tirón en breve, fueron muy buenos los resultados y el consenso dá potencial

http://www.4-traders.com/PARAGON-CARE-LTD-10356314/consensus/

[jerez1]

Corregida, debe dar tirón en breve, fueron muy buenos los resultados y el consenso dá potencial

http://www.4-traders.com/PARAGON-CAR...314/consensus/

Infravalorada, su valor intrínseco está en 1,35 aud

Should You Buy Paragon Care Limited (ASX:PGC)?

Lacy Summers September 19, 2017
Paragon Care Limited (ASX:PGC), a healthcare equipment and services company based in Australia, led the ASX gainers with a relatively large price hike in the past couple of weeks. Less covered, small-stocks like PGC sees more of an opportunity for mispricing due to the lack of information available to the public, which can be a good thing. So, could PGC still be trading at a low price relative to its actual value? Let’s examine PGC’s valuation and outlook in more detail to determine if there’s still a bargain opportunity. View our latest analysis for Paragon Care

Is PGC still cheap?

Great news for investors – PGC is still trading at a fairly cheap price. According to my valuation, the intrinsic value for the stock is $1.36 which is above what the market is valuing the company at the moment. This indicates a potential opportunity to buy low. PGC’s share price also seems relatively stable compared to the rest of the market, as indicated by its low beta. If you believe the share price should eventually reach its true value, a low beta could suggest it is unlikely to rapidly do so anytime soon, and once it’s there, it may be hard to fall back down into an attractive buying range.
What kind of growth will PGC generate?

ASX:PGC Future Profit Sep 19th 17 Future outlook is an important aspect when you’re looking at buying a stock, especially if you are an investor looking for growth in your portfolio.Buying a great company with a robust outlook at a cheap price is always a good investment, so let’s also take a look at PGC future expectations. With profit expected to grow by 38.24% over the next couple of years, the future seems bright for PGC. It looks like higher cash flows is on the cards for the stock, which should feed into a higher share valuation. What this means for you:

Are you a shareholder? Since PGC is currently undervalued, it may be a great time to accumulate more of your holdings in the stock. With an optimistic outlook on the horizon, it seems like this growth has not yet been fully factored into the share price. However, there are also other factors such as capital structure to consider, which could explain the current undervaluation.
Are you a potential investor? If you’ve been keeping an eye on PGC for a while, now might be the time to make a leap. Its prosperous future outlook isn’t fully reflected in the current share price yet, which means it’s not too late to buy PGC. But before you make any investment decisions, consider other factors such as the track record of its management team, in order to make a well-informed investment decision.
Price is just the tip of the iceberg. Dig deeper into what truly matters – the fundamentals – before you make a decision on Paragon Care. You can find everything you need to know about PGC in the latest infographic research report. If you are no longer interested in Paragon Care, you can use our free platform to see my list of over 50 other stocks with a high growth potential.
Daniel Loeb has achieved 16.2% annualized returns over the last 20 years. What is he holding today?

Founder of the event-driven, value-oriented hedge fund Third Point, Daniel Loeb is one of the most successful activist investors on the market today. Explore his portfolio’s top holdings, see how he diversifies his investments, past performance and growth estimates. Click here to view a FREE detailed infographic analysis of Daniel Loeb’s investment portfolio.

[jerez1]

https://www.paragoncare.com.au/wp-content/uploads/PGC-Bell-Potter-Report-FY18-Another-Year-of-Growth-Paragon-Care_20170914.pdf

[jerez1]

En breve publican, buen momento para entrar, está corregida y con todas las adquisiciones y desarrollo que hay en temas médicos en Australia, deben haber buen momentum, Además, per 12.

[jerez1]

Paragon Care ready for SA expansion with new US partner, office facility and warehouse

Valerina Changarathil, The Advertiser
December 27, 2017 6:03am


Subscriber only

Ads by Kiosked

VICTORIAN medical equipment supplier Paragon Care has roped in a US partner to expand it distribution footprint in SA.

Paragon Care will be the exclusive distributor for US medical products supplier Smiths Medical and their suite of products into SA.
Australian sharemarket-listed Paragon is currently finalising fitout and logistics for a new warehouse and office space in Wingfield, which is due to open next month.
Managing director Mark Simari said the company was talking to “a number of other global companies to replicate this initiative and leverage our new warehouse operations”
“Our SA strategy is to partner with global healthcare manufacturers in territories where they would prefer to enjoy a partnership rather than set up their own operations in that territory,” Mr Simari said.
“We run a similar operation in WA very successfully and are looking to achieve the same in SA.
“This complements our overall strategy of being a national supplier of healthcare products and services across the sector.”
The company, which posted record revenues of $117.2 million in FY17, expects revenue to come in at between $125 million and $135 million, boosted by acquisitions.
The group has bought 11 businesses in the past seven years.
On Wednesday, it announced two new purchases in NSW — Insight Surgical for $5 million and Medtech Solutions for $2.4 million.
It’s $8.5 million buyout of the Seqirus (CSL) immunohaematology business is in progress and is expected to be settled by March.
The office will represent Paragon-owned Western Biomedical brands and will provide a full logistics solution. It will also house local representatives for the current Paragon Care brands including Designs for Vision, Paragon Care and a new Service and Technology division.
Paragon Care has an existing distribution arrangement with Anaequip in SA, which will remain unchanged.
The South Australian operation will be headed up by Susanne Wilson.
Paragon Care supplies medical equipment, devices and consumables for the Australian and New Zealand healthcare market.

[jerez1]

Paragon Care ready for SA expansion with new US partner, office facility and warehouse

Valerina Changarathil, The Advertiser
December 27, 2017 6:03am


Subscriber only

Ads by Kiosked

VICTORIAN medical equipment supplier Paragon Care has roped in a US partner to expand it distribution footprint in SA.

Paragon Care will be the exclusive distributor for US medical products supplier Smiths Medical and their suite of products into SA.
Australian sharemarket-listed Paragon is currently finalising fitout and logistics for a new warehouse and office space in Wingfield, which is due to open next month.
Managing director Mark Simari said the company was talking to “a number of other global companies to replicate this initiative and leverage our new warehouse operations”
“Our SA strategy is to partner with global healthcare manufacturers in territories where they would prefer to enjoy a partnership rather than set up their own operations in that territory,” Mr Simari said.
“We run a similar operation in WA very successfully and are looking to achieve the same in SA.
“This complements our overall strategy of being a national supplier of healthcare products and services across the sector.”
The company, which posted record revenues of $117.2 million in FY17, expects revenue to come in at between $125 million and $135 million, boosted by acquisitions.
The group has bought 11 businesses in the past seven years.
On Wednesday, it announced two new purchases in NSW — Insight Surgical for $5 million and Medtech Solutions for $2.4 million.
It’s $8.5 million buyout of the Seqirus (CSL) immunohaematology business is in progress and is expected to be settled by March.
The office will represent Paragon-owned Western Biomedical brands and will provide a full logistics solution. It will also house local representatives for the current Paragon Care brands including Designs for Vision, Paragon Care and a new Service and Technology division.
Paragon Care has an existing distribution arrangement with Anaequip in SA, which will remain unchanged.
The South Australian operation will be headed up by Susanne Wilson.
Paragon Care supplies medical equipment, devices and consumables for the Australian and New Zealand healthcare market.

Parece finalizada la corrección,, le veo mucho crecimiento. Van a adquirir otras empresas para seguir creciendo.

The Paragon Care Ltd (ASX: PGC) share price has fallen by about 10% since the start of 2018, but over the past five years has grown by 152%.
Paragon is a small cap healthcare business that supplies medical products and equipment like beds to hospitals, aged care facilities and other healthcare locations.
I believe there are several reasons to like Paragon, here are a few of them:
Acquisition expansion
Paragon’s key strategy is to expand the business through acquisitions. A simple roll-up strategy can work out okay, but I think Paragon’s strategy is quite effective.
It is steadily acquiring businesses that supply different healthcare products with different sets of customers. This means that over time, as Paragon makes more bolt-on acquisitions, it can offer its clients more of their purchasing needs and the new acquisitions may provide Paragon with another set of clients.
For example, Paragon recently acquired Surgical Specialties Group for $32.4 million. This acquisition is expected to be earnings per share (EPS) accretive in FY18, whilst adding $30 million of annual revenue and $4.9 million of earnings before interest, tax, depreciation and amortisation (EBITDA).
Customers
Paragon supplies a variety of different healthcare markets including aged care, hospital & acute care, primary care, eye care, storage solutions, service & technology management, e-health and diagnostics.
According to the company, before its recent acquisitions, 80% of Paragon’s revenue came from hospitals and 80% of that came from the public system whilst the other 20% came from the private sector.
With Australia’s clear ageing demographics it’s obvious the growth in total healthcare expenditure will continue to grow and Paragon could benefit from this if it becomes a major supplier for the public sector.
Underlying growth and dividend
https://www.fool.com.au/2018/05/08/w...m-opportunity/

[jerez1]

Parece finalizada la corrección,, le veo mucho crecimiento. Van a adquirir otras empresas para seguir creciendo.

The Paragon Care Ltd (ASX: PGC) share price has fallen by about 10% since the start of 2018, but over the past five years has grown by 152%.
Paragon is a small cap healthcare business that supplies medical products and equipment like beds to hospitals, aged care facilities and other healthcare locations.
I believe there are several reasons to like Paragon, here are a few of them:
Acquisition expansion
Paragon’s key strategy is to expand the business through acquisitions. A simple roll-up strategy can work out okay, but I think Paragon’s strategy is quite effective.
It is steadily acquiring businesses that supply different healthcare products with different sets of customers. This means that over time, as Paragon makes more bolt-on acquisitions, it can offer its clients more of their purchasing needs and the new acquisitions may provide Paragon with another set of clients.
For example, Paragon recently acquired Surgical Specialties Group for $32.4 million. This acquisition is expected to be earnings per share (EPS) accretive in FY18, whilst adding $30 million of annual revenue and $4.9 million of earnings before interest, tax, depreciation and amortisation (EBITDA).
Customers
Paragon supplies a variety of different healthcare markets including aged care, hospital & acute care, primary care, eye care, storage solutions, service & technology management, e-health and diagnostics.
According to the company, before its recent acquisitions, 80% of Paragon’s revenue came from hospitals and 80% of that came from the public system whilst the other 20% came from the private sector.
With Australia’s clear ageing demographics it’s obvious the growth in total healthcare expenditure will continue to grow and Paragon could benefit from this if it becomes a major supplier for the public sector.
Underlying growth and dividend
https://www.fool.com.au/2018/05/08/w...m-opportunity/

Buen momento, finalizó la corrección y se va a cercando a los máximos del pasado año

[jerez1]

Buen momento, finalizó la corrección y se va a cercando a los máximos del pasado año

Buen tirón, casi un 4% sube

[jerez1]

Buen tirón, casi un 4% sube

Rompió la resistencia de 81c, próxima resistencia los 91c

[jerez1]

Rompió la resistencia de 81c, próxima resistencia los 91c

Fuerte compra

https://es.investing.com/equities/paragon-care-ltd-technical

[jerez1]

Fuerte compra

https://es.investing.com/equities/pa...-ltd-technical

Paragon Care has a new asset in its sights
Share
11:30 06 Jun 2018
Paragon has been acquiring businesses in the healthcare sector.
Paragon Care has a new asset in its sights
The company's shares are in pre-open
Paragon Care Ltd (ASX:PGC) is back on the acquisition trail, with the ASX granting the company a trading halt this morning pending its next bolt on.

Earlier in the year Paragon outlined nine acquisition opportunities in the healthcare sector during the company's $69.8 million capital raising.


Seven of these have been completed so far.

Paragon is also set for a busy June quarter, as historically over a third of the year’s business has normally been transacted during this period.

The company is a provider of medical equipment, devices and consumables for the Australian and New Zealand healthcare market.

The halt will remain in place until the opening of trade on Friday 8 June 2018, or earlier if an announcement is made to the market.



Share



Paragon Care Ltd has a new asset in its sights

[jerez1]

Paragon Care has a new asset in its sights
Share
11:30 06 Jun 2018
Paragon has been acquiring businesses in the healthcare sector.
Paragon Care has a new asset in its sights
The company's shares are in pre-open
Paragon Care Ltd (ASX:PGC) is back on the acquisition trail, with the ASX granting the company a trading halt this morning pending its next bolt on.

Earlier in the year Paragon outlined nine acquisition opportunities in the healthcare sector during the company's $69.8 million capital raising.


Seven of these have been completed so far.

Paragon is also set for a busy June quarter, as historically over a third of the year’s business has normally been transacted during this period.

The company is a provider of medical equipment, devices and consumables for the Australian and New Zealand healthcare market.

The halt will remain in place until the opening of trade on Friday 8 June 2018, or earlier if an announcement is made to the market.



Share



Paragon Care Ltd has a new asset in its sights

Adquieren Rem Systems, sube un 4%

Should you buy Paragon Care Ltd. (ASX:PGC) after its acquisition spree?
Tommaso Autorino | June 8, 2018 | More on: PGC

Shares in Paragon Care Ltd (ASX: PGC) rose 3% to $0.84c on Friday morning’s trade, after the company announced the acquisition of New Zealand-based healthcare business REM Systems for a net enterprise value of NZ$54 million (about $50 million).
The details of the transaction
Paragon will settle 80% of the purchase in cash and the rest through the issuance of 12.7 million shares at the 30-day volume-weighted average price of $0.76c. In addition, the deal includes earn-out provision of 4.5 times FY20 and FY21 incremental EBITDA from the acquisition. REM’s vendors and executive management will stay with the business throughout the earn-out period.
REM has a forecast FY18 revenue base of NZ$68 million and EBITDA of NZ$7 million.
Funding for the transaction derives partly from Paragon’s recent $70 million capital raising and partly from an increased debt facility with National Australia Bank (ASX: NAB). Paragon’s net debt to EBITDA ratio is expected to be between 2x and 2.5x following the acquisition.
Strategic rationale
Paragon’s Chairman, Shane Tanner, described REM as a “near perfect strategic fit”.
Through a series of acquisitions of suppliers of the healthcare sector – seven in the last four months –Paragon has grown to become an integrated healthcare equipment and services provider for acute, aged and primary care in Australia and New Zealand.
The acquisition of REM is particularly significant given the size of the target – in comparison with Paragon’s market capitalisation of $230 million – and the fact that REM itself is a diversified medical distribution company supplying 4,000 customers including acute care hospitals, day surgeries, medical practices and veterinary clinics throughout New Zealand and Australia, with an articulate structure that resembles Paragon’s.
Despite its strong organic growth – in the range of 6% to 8% per annum over recent years, according to Paragon’s announcement – REM is still a family run business
The acquisition is anticipated to be in excess of 10% EPS accretive in FY19 and beyond.
Foolish takeaway
I’m usually quite wary of growth built on an acquisition spree, but in this case I think the move makes perfect sense, given the homogeneity between Paragon and REM.
Based on the company’s forecast, the stock trades at just 11x FY18 earnings. With this valuation, I think Paragon is a good option to gain exposure to the healthcare sector, which is poised to grow in coming years as the Australian population ages.
But there’s another industry ready to take off. Click here to claim your free report.
7 of 8 People Are Clueless About This Trillion-Dollar Market
One of our investors has recently returned from a research trip to Silicon Valley... and has a warning for fellow investors:
Because he works for an organization dedicated to spreading great investing ideas, his video report is free today... so you can see it and decide for yourself.
Don't miss your chance click here to learn about this warning and how you might be able to profit!
Motley Fool contributor Tommaso Autorino has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of National Australia Bank Limited. The Motley Fool Australia has recommended Paragon Care Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.